Cite

    Foster, C. et al. (2021). Immune‐related adverse events are associated with improved response, progression‐free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors. Cancer. 127 (24), pp. 4565-4573. [Online].